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Introduction: HLA-B27 genotyping is commonly used to support a diagnosis of ankylosing spondylitis (AS). A
recent study has suggested that HLA-B27 may adversely affect longevity. The objectives of this study were to
determine, for the first time, the prevalence of HLA-B27 in the New Zealand population, and to test whether
HLA-B27 prevalence declines with age.
Methods: 117 Caucasian controls, 111 New Zealand Māori controls, and 176 AS patients were directly genotyped
for HLA-B27 using PCR-SSP. These participants and a further 1103 Caucasian controls were genotyped for the
HLA-B27 tagging single nucleotide polymorphisms (SNPs) rs4349859 and rs116488202. All AS patients testing positive
for HLA-B27 of New Zealand Māori ancestry underwent high resolution typing to determine sub-allele status.
Results: HLA-B27 prevalence was 9.2% in New Zealand Caucasian controls and 6.5% in Māori controls. No decline in
HLA-B27 prevalence with age was detected in Caucasian controls (p = 0.92). Concordance between HLA-B27 and SNP
genotypes was 98.7-99.3% in Caucasians and 76.9-86% in Māori. Of the 14 AS patients of Māori ancestry, 1 was
negative for HLA-B27, 10 were positive for HLAB*2705, and 3 positive for HLAB*2704. All cases of genotype discordance
were explained by the presence of HLAB*2704.
Conclusions: HLA-B27 prevalence in New Zealand Caucasians is consistent with that of Northern European populations
and did not decline with increasing age. In Māori with AS who were HLA-B27 positive, 76.9% were positive for
HLA-B*2705, suggesting that genetic susceptibility to AS in Māori is primarily due to admixture with Caucasians.Introduction
Human leukocyte antigen (HLA) class I molecule HLA-
B27 was the first genetic risk factor identified as asso-
ciating with ankylosing spondylitis (AS) and remains the
most important risk locus for this archetypal spondyloar-
thropathy [1]. Twin and family studies estimate that
HLA-B27 accounts for 20 to 50% of the total genetic
risk of AS [2] and confers an odds ratio in European
Caucasians >100 for AS [1]. To date, 100 suballeles of
HLA-B27 have been described [1]. Of these suballeles,
HLA-B*2701, HLA-B*2702, HLA-B*2704, HLA-B*2705,
and HLA-B*2707 have been associated with AS [3]. As
yet there are few data on whether the other suballeles
are associated with altered disease susceptibility.* Correspondence: rebecca.roberts@otago.ac.nz
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reproduction in any medium, provided the orData from murine models suggest that HLA-B27 is di-
rectly involved in the pathogenesis of AS and it is recog-
nised in human populations that the prevalence of the
gene reflects the prevalence of AS [1]. However, the
mechanism by which this HLA protein contributes to
disease remains a source of intense speculation. Hypo-
theses for the role of HLA-B27 in the pathogenesis of AS
can be broadly divided into those related to aberrant pro-
cessing of antigenic peptides and endoplasmic reticulum
stress resulting from a tendency for HLA-B27 to misfold
and form homo-dimers. The molecular mimicry/cross-
tolerance theory relating to specific bacterial antigens is
currently less favoured [1].
The association of HLAB-27 within the broader group
of spondyloarthropathies (SpA) varies significantly, ran-
ging from <50% in psoriatic, enteropathic, and inflam-
matory bowel disease-associated SpA, to 80% in reactive
arthritis, to >95% in AS. The frequency of the HLA-B27
allele also varies widely across populations [4]. Both al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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been observed for HLA-B27 prevalence in the Northern
Hemisphere. It is hypothesised that these gradients result
from the negative selection pressure exerted by malaria
[5]. In regions where malaria is endemic, the prevalence of
HLAB-27 is low, and vice versa [5]. HLA-B27 is highly
prevalent in Northern Eurasia and North America, with
10 to 16% of Norwegians, Swedes and Icelanders and
25 to 50% of Inuit, Yupik and Indigenous Northern
Americans (for example, Haida and Bella Coola) carrying
this allele [4]. HLA-B27 prevalence decreases to 9.5% in
the United Kingdom [6], and further decreases to 2 to
6% in Mediterranean regions [4]. In a similar manner,
HLA-B27 prevalence decreases from west to east. In
Southeast Asia prevalence of HLA-B27 can exceed 12%,
but in mainland China the range is between 2 and 6% [4].
HLA-B27 prevalence also varies significantly within the
Pacific Islands. In Melanesia the prevalence is high, where-
as HLA-B27 is uncommon in Micronesia and absent in
unmixed native populations of Southeast Polynesia [4].
At present there is a paucity of prevalence data regar-
ding the HLA-B27 in the New Zealand population,
including indigenous Maori. Three previous studies have
included New Zealanders. In the first study, Gonzalez-
Roces and colleagues conducted a worldwide survey of
HLA-B27 polymorphisms, and included 12 disease-free
New Zealand Māori who tested positive for HLA-B27
[3]. The second study related to the prevalence of HLA-
B27 in patients presenting to an acute eye service with a
history of bilateral or recurrent anterior uveitis. In this
study 124 consecutive patients undergoing uveitis
screening were typed for HLA-B27. Of these patients, 44
were positive for HLA-B27 and 41% (n = 18 out of 44)
showed early radiologic evidence of AS [7]. No ethnicity
data were available for this patient dataset. In the third
study, 116 patients with SpA, 23 patients with uveitis,
and 47 patients of unknown disease status were identi-
fied by the New Zealand Blood Service as serologically
positive for HLA-B27 and sequenced to determine the
suballele prevalence [8]. No healthy controls were in-
cluded in either of the two latter studies, and none of
the SpA patients in the study of Stewart were assessed
clinically to determine whether they met classification
criteria for AS [8]. None of these three studies provided
prevalence data for HLA-B27 in New Zealand. Given
that HLA-B27 remains the most important genetic risk
factor for the development of AS, and testing is fre-
quently used to assist diagnosis, there is clinical rele-
vance to establishing the prevalence of this HLA allele,
which could help with the planning of health resource
allocation in New Zealand.
In countries with a high prevalence of AS, dedicated
clinics are increasingly being established to assist with
the assessment of patients an initiation of anti-tumournecrosis factor therapies. Furthermore, a recent HLA-B27
prevalence study from the United States reported a signifi-
cant decline in the prevalence of HLA-B27 with age [9].
The overall age-adjusted HLA-B27 prevalence in the
United States was estimated at 6.1% (95% confidence
interval = 5.3 to 10.4), but when age groups were exa-
mined separately the prevalence in 40 to 49 year olds was
8.1% (95% confidence interval = 5.8 to 11.2) and dropped
to 3.6% (95% confidence interval = 2.2 to 5.8) in 50 to
69 year olds [9]. This observation raises the possibility that
HLA-B27 status has a detrimental effect on longevity.
Our study had three aims. The first aim was to deter-
mine the prevalence of HLA-B27 in three large control
datasets (two Caucasian, one New Zealand Māori) and
one AS dataset using single-specific primer polymerase
chain reaction (PCR-SSP) and the HLA-B27 tagging
single nucleotide polymorphisms (SNPs) rs4349859 and
rs116488202. The second aim was to determine HLA-
B27 suballeles in AS patients of New Zealand Māori
ancestry. The third aim was to investigate whether the
decline in HLA-B27 prevalence with increasing age, ob-




A total of 176 patients with AS, fulfilling the modified
New York criteria [10], were genotyped as part of an on-
going New-Zealand-wide longitudinal study of AS. All pa-
tients with AS were assessed clinically at the time blood
samples were obtained for genetic testing. The assessment
provided an indication of disease severity at the time of
enrolment into the genetic study. Disease activity was
assessed using the Bath Ankylosing Spondylitis Disease
Activity Index (range 0 to 10) [11], and C-reactive protein
(mg/l) was measured at Southern Community Labora-
tories (normal range for laboratory <1 mg/l). The Bath
Ankylosing Spondylitis Functional Index (range 0 to 10)
[12] assessed functional limitation in the AS patients. Fol-
lowing a clinical examination, spinal mobility was assessed
using the Bath AS Metrology Index (range 0 to 10), higher
scores indicating increasing limitation of mobility [13].
Treatment with anti-tumour necrosis factor alpha inhi-
bitors was recorded in all patients. This acts a marker of
disease severity, since all patients receiving such treatment
in New Zealand are required to have bilateral sacroiliitis
on X-ray, a Bath Ankylosing Spondylitis Disease Activity
Index >6.0 and limitation of spinal flexion and/or chest
expansion.
Two Caucasian healthy control datasets (A1, 485 con-
trols; and A2, 735 controls) and 111 New Zealand Māori
controls were included in this study. The A1 and A2 data-
sets were screened for relevant diseases using self-reporting
questionnaires and for A2 controls, physiological (ankle
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and waist–hip ratio) and ultrasound (aorta and carotid
arteries) assessments of vascular disease status along with
a review of their current medications were also performed.
Each control dataset has been described in detail else-
where [14,15]. A summary of the basic demographics of
patients and controls is presented in Table 1. Self-reported
ancestry data were available for all study participants. To
be included as a Māori control or Māori AS patient, an
individual needed a minimum of two Māori grandparents.
Informed written consent was obtained from all study par-
ticipants, and ethical approval for this study was granted
by the Upper South and Lower South Regional Ethics
Committees of New Zealand.
DNA extraction and SNP genotyping
DNA was obtained from peripheral blood using guanidine
isothiocyanate extraction. The major histocompatibility
complex (MHC) SNP rs4349859 has been found to
tag the major Caucasian AS-associated suballeles HLA-
B*2702, HLA-B*2705 and HLA-B*2708 with 98% sensi-
tivity and 99% specificity. However, this SNP does not tag
the African AS-associated suballele HLA-B*2703, nor
the Asian suballeles HLA-B*2704, HLA-B*2706, and
HLA-B*2707 [16]. More recently another tagging SNP,
rs116488202, has been identified that may accurately tag
both Caucasian and Asian HLA-B27 suballeles [17]. Geno-
typing of rs4349859 and rs116488202 was carried out
using a predesigned TaqMan® SNP genotyping assay
(Assay ID number C__28023949_10) and a custom
designed TaqMan® SNP genotyping assay (Assay IDTable 1 Basic demographics of the New Zealand control and
Demographic Caucasian controls, A1 Caucasian controls
(n = 485) (n = 735)
Males (%) 200/485 (41.2) 570/735 (77.5)
Mean age (years) 44.9 69.6
Ethnicity 100% Caucasian 100% Caucasian
Mean (SD) BASDAI – –
Mean (SD) BASFI – –
Mean (SD) BASMI – –
Mean (SD) CRP – –
Patients receiving TNFi (%) – –
Comorbidities (%)
Osteoarthritis 3 (0.6) 125 (29.0)
Rheumatoid arthritis 1 (0.2) 28 (6.5)
Other forms of arthritis – 10 (2.3)
IBD 1 (0.2) –
BASDAI, Bath Ankylosing Spondylitis Activity Index; BASFI, Bath Ankylosing Spondyl
CRP, C-reactive protein; IBD, inflammatory bowel disease; SD, standard deviation; TNnumber AHCS8KA), respectively, as per the manufacturer’s
instructions (Applied Biosystems, Carlsbad, California, USA).
Briefly, the assays were performed in a total reaction volume
of 5 μl containing 2.5 μl of 2× TaqMan® Universal Master
Mix (Roche Molecular Systems Inc, Branchburg, NJ, USA),
0.25 μl of 20× working mix of SNP genotyping assay and
12 ng genomic DNA. The PCR was performed in a Roche
LightCycler 480 real-time PCR system, with an activation
step of 10 minutes at 95°C, following by 40 cycles of
denaturation (15 seconds at 92°C) and annealing/extension
(1 minute at 60°C). Genotypes were assigned using the
endpoint genotyping analysis software. The accuracy of
the TaqMan® SNP assays was confirmed by repeat analysis
of 10% of samples. Concordance between original and
repeat genotype calls was 100% for both assays. PLINK
software [18] was used to test for deviations in Hardy–
Weinberg equilibrium.
Our control datasets (A1, 485 controls vs. A2, 735
controls) had 99% power to detect the effect size of odds
ratio = 0.4 (α = 0.05) for age, previously reported by
Reveille and colleagues [9].
HLA-B27 typing
Direct typing of the HLA-B27 allele was performed
by the Canterbury Health Laboratories (Christchurch,
New Zealand) and Waikato Hospital Laboratory (Hamilton,
New Zealand) on 117 Caucasian controls, 111 New
Zealand Māori controls, and 176 AS patients. All AS
patients of New Zealand Māori ancestry who tested
positive for HLA-B27 by PCR-SSP underwent high-
resolution HLA typing to determine their HLA-B27ankylosing spondylitis datasets
, A2 New Zealand Māori controls AS patients (New York criteria)
(n = 111) (n = 176)
30/111 (27.0) 113/152 (74.3)
41.7 46.7










itis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index;
Fi, tumour necrosis factor inhibitors.
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by the Immunogenetics and Transplantation Laboratory
(University of California, San Francisco, CA, USA) using
DNA sequence-based typing.
Results
A total of 117 Caucasian controls, 111 New Zealand
Māori controls and 176 AS patients were typed for
HLA-B27 using PCR-SSP. The prevalence of HLA-B27
in New Zealand Caucasians, Māori, and AS patients was
noted as 7.7%, 6.5% and 93.2%, respectively. These study
participants, as well as 1,103 additional Caucasian con-
trols, were then genotyped for the HLA-B27 tagging
SNPs rs4349859 and rs116488202 (Table 2). The con-
cordance between HLA-B27 and tagging SNP genotypes
was 100% in New Zealand Caucasian controls and 98.7 to
99.3% in New Zealand Caucasians with AS, but declined to
76.9 to 85.7% in AS patients and controls of New Zealand
Māori ancestry (Table 2). The Caucasian controls com-
prised two datasets (A1 and A2). The combined prevalence
of HLA-B27 in these datasets, inferred by rs4349859
genotype, was 9.2% (11/1,220). Significant deviation from
Hardy–Weinberg equilibrium was observed for rs4349859
in the AS dataset (P = 2.09 × 10–11), whereas no deviations
from Hardy–Weinberg equilibrium were observed in any
of the control datasets for this SNP (P >0.05).
A total of 14 patients in the AS dataset were identified
as New Zealand Māori by self-report (Table 1). Of these
14 patients one was HLA-B27-negative, and 13 were
HLA-B27-positive. All 14 patients went forward to DNA
sequence-based typing to determine their HLA-B27
suballele status. Ten were positive for the European
suballele HLAB*2705, and three for the Asian suballele
HLAB*2704.
The two Caucasian control datasets, A1 and A2, were
used to determine whether HLA-B27 prevalence de-
clined with increasing age. Participants in the A1 dataset
had a mean age of 44.9 years whereas participants in theTable 2 Concordance between HLA-B27 and tagging SNP rs43
controls and ankylosing spondylitis patients
Phenotype Frequency
HLA-B27-positiveα rs4349859-po
Controls Caucasian 9/117 (7.7) 9/117 (7.
New Zealand Māori 7/107 (6.5) 6/107 (5.
AS Overall 164/176 (93.2) 159/176 (9
Caucasian 151/162 (93.2) 149/162 (9
New Zealand Māori 13/14 (92.9) 10/14 (71
AS, ankylosing spondylitis; SNP, single nucleotide polymorphism.
αHLA-B27 status determined by human leucocyte antigen (HLA) typing.
bStudy participants were positive if heterozygous or homozygous for the minor alle
cOne patient was HLA-B*2705-positive by typing but was negative for the minor alle
dOne patient was HLA-B*2705-positive by typing but was negative for the minor allA2 dataset had a mean age of 69.9 years (Table 3). HLA-
B27 prevalence for each dataset was inferred from the
rs4349859 genotype. In the A1 dataset, 9.1% (44/485)
were heterozygous or homozygous for the minor (A)
allele compared with 9.2% (68/735) in the A2 dataset
(P = 0.92) (Table 3).
Discussion
To our knowledge this is the first study to investigate
HLA-B27 in a large number of Caucasian (n = 1,220)
and Māori (n = 111) controls to determine prevalence of
this AS-associated allele in the New Zealand population.
The prevalence of HLA-B27 in New Zealand Caucasian
controls (9.2%) was similar to the prevalence of 9.5%
previously reported in a dataset of 5,926 UK controls
[6]. Similarly, the overall HLA-B27 prevalence of 93.2%
in our predominately Caucasian AS patient dataset was
consistent with the prevalence previously reported in
overseas Caucasian AS datasets [6]. There is a paucity of
existing data regarding the prevalence of AS in Māori.
Concordance between the tagging SNPs and HLA-B27
genotypes was 98.7% for rs4349859 and 99.3% for
rs116488202 in the Caucasian AS patients but declined to
76.9% for both SNPs in AS patients of New Zealand Māori
ancestry (Table 2). A previous study found that SNP
rs116488202 tagged HLA-B27 more accurately than
rs4349859 in both Caucasians and Asians [17]. In our
study, whilst SNP rs116488202 tagged HLA-B27 more
accurately for Caucasians this was not the case for New
Zealand Māori. Subsequent high-resolution HLA typing
found the three Māori patients with discordant genotypes
were all positive for the Asian AS-associated HLAB*2704
suballele, which neither rs4349859 nor rs116488202 geno-
typing identified [16]. To assess the ability of rs116488202
to tag HLA-B27 suballeles more fully, we sent DNA from
three Asian patients (one Filipino, one Han Chinese, one
Thai) with AS for high-resolution HLA typing. One
patient was found to carry HLAB*2705 and two patients49859 and rs116488202 genotypes in New Zealand
(n (%)) Genotype concordance (%)
sitiveb rs116488202-positive rs4349859 rs116488202
7) 9/117 (7.7) 100.0 100.0
6) 6/107 (5.6) 85.7 85.7
0.3) 159/176 (90.3) 96.9 97.6
1.9)c 150/162 (92.6)d 98.7 99.3
.4) 10/14 (71.4) 76.9 76.9
le of rs4349859 or rs116488202.
le of both tagging SNPs.
ele of rs4349859.
Table 3 Genotype and minor allele frequency of the HLA-B27 tagging SNP rs4349859 in New Zealand Caucasian
controls stratified according to age





A1 (n = 485) 44.9 441 (0.909) 42 (0.087) 2 (0.004) 46 (0.047) 44 (0.091) 0.92
A2 (n = 735) 69.9 667 (0.907) 65 (0.088) 3 (0.004) 71 (0.048) 68 (0.092)
SNP, single nucleotide polymorphism.
aMinor allele frequency.
bDetermined by adding together the rs4349859 AG and AA genotypes.
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genotyping was only able to identify the patient who car-
ried the suballele HLAB*2705 as HLA-B27-positive. These
findings suggest that whilst rs116488202 is a more accur-
ate tagging SNP for HLA-B27 in Caucasians, it does not
tag HLA-B27 any more strongly than rs43439859 in
Asians or New Zealand Māori. However, it is important to
note that our study only had 14 New Zealand Māori and
three Asian participants, and therefore does not have the
power to allow us to draw any firm conclusions on the
relative performance of these two tagging SNPs in indivi-
duals of Māori or Asian ancestry.
Direct HLA typing by PCR-SSP typically costs around
NZD$55 per sample, requires 2 μg DNA, and has a 14-day
turnaround. In comparison, genotyping by TaqMan® costs
NZD$5 per sample, requires 8 to 16 ng DNA, and can be
completed within 4 to 8 hours. Given the high con-
cordance between HLA-B27 and SNP genotypes observed
in New Zealand Caucasians (Table 2), genotyping for
rs4349859 or rs116488202 could serve as a rapid and
inexpensive way of reliably establishing HLA-B27 status in
predominately Caucasian AS datasets.
The distribution of AS-associated HLA-B27 suballeles
differs significantly across populations. HLAB*2705 is
found in all racial groups and thus is widely considered to
be the ancestral suballele from which all other variants of
HLA-B27 have arisen. HLAB*2705 is the most common
suballele in Caucasians, but a second, Caucasian-specific
suballele (HLAB*2702) is also seen, albeit at a much lower
frequency. HLAB*2704 is the most common AS-asso-
ciated suballele in East Asians but has not been reported
in Caucasians [3]. Of the 11 Māori AS patients who
underwent high-resolution typing, 10 carried HLAB*2705
and three carried HLAB*2704. In the only previous study
of HLAB-27 prevalence to include New Zealand Māori
[3], seven of 12 (58%) individuals carried the HLAB*2705
allele and five individuals (42%) carried the HLAB*2704
allele. The presence of the Asian-specific suballele
HLAB*2704 in New Zealand Māori supports a recent
investigation into genetic structure of Pacific Islanders,
suggesting Polynesians are closely related to Taiwanese
Aboriginal populations [19], a finding strongly supportedby anthropological evidence and a common Austronesian
language structure. A study of Taiwanese Aboriginal
populations demonstrated a differential prevalence of
HLA-B27 amongst different tribes, with a high prevalence
of HLA-B27 (9.2%) in Atayal Aborigines, 2.1% in the
Paiwan and none in the Rukai. HLAB*2704 was the only
suballele identified in the aboriginal population [20]. In
the current study, AS patients of New Zealand Māori
ancestry have a low prevalence of this HLAB*2704, indi-
cating that genetic susceptibility to AS in this popula-
tion is primarily due to significant recent admixture
with Caucasians.
The final aim of our study was to investigate the po-
tential link between HLA-B27 status and longevity. A
recent study of HLA-B27 in 2,320 US adults reported a
significant decline in the prevalence of the HLA-B27
allele with age, which remained significant after adjust-
ment for sex and race [9]. Although the decreasing
linear trend in HLA-B27 prevalence with age was not
entirely consistent in this dataset [9], the result suggests
that HLA-B27 may negatively impact on longevity, a po-
tentially devastating observation, given that HLA-B27 is
one of the most widely employed clinical genetic tests.
Previous investigations offer a possible biological ratio-
nale for this observation, although clinical studies fol-
lowing patients with AS have actually shown a reduced
standardised mortality ratio in patients with AS [21].
HLA-B27 has been shown to increase susceptibility
to intracellular bacterial pathogens that could in turn
increase the risk of atherosclerosis and valvular heart
disease, and thus reduce life expectancy. In the current
study, however, we found no evidence of a similar
decline in HLA-B27 prevalence in two New Zealand
Caucasian datasets of significantly different mean age.
Conclusions
HLA-B27 is commonly tested to assist in the diagnosis
of AS. Despite the clinical relevance of this locus there is
a paucity of prevalence data for HLA-B27 in the New
Zealand population. Our study has established, for the
first time, the prevalence of HLA-B27 in New Zealand
Caucasians and Māori. We have found that the
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parable with the prevalence rates observed in Northern
European populations, and did not decline with increasing
age, suggesting that HLA-B27 does not adversely affect
longevity in the New Zealand Caucasians. Furthermore,
the prevalence of HLA-B27 allele in New Zealand Māori
controls (6.5%) was higher than expected. This increase in
HLA-B27 prevalence and the preponderance of the AS-
associated suballele in HLAB*2705 in Māori patients indi-
cates that AS susceptibility in New Zealand Māori is
largely due to admixture with Caucasians. Finally the high
prevalence of HLA-B27 in the studied population implies
a similarly high prevalence of AS in New Zealand. Since
AS is associated with both significant negative health and
socioeconomic effects, this finding will prove helpful in
planning the allocation of publicly funded health resources
in New Zealand.
Abbreviations
AS: Ankylosing spondylitis; HLA: Human leucocyte antigen; PCR: Polymerase
chain reaction; SNP: Single nucleotide polymorphism;
SpA: Spondyloarthropathies; SSP: Single-specific primer.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RLR and SMS contributed equally to this study. RLR participated in the
design of the study, data analysis, and drafting the manuscript. MCW
performed the tagging SNP genotyping of patients and controls, and
participated in data analysis and the drafting of the manuscript. GTJ and
AMvR provided the A2 control cohort. TRM provided the A1 control cohort.
AH, DW, LKS, DC, and JH provided AS patients and associated phenotype
data. SMS participated in the design of the study, data analysis, drafting of
the manuscript, and coordinated patient recruitment from different centres
within New Zealand. All authors read and approved the final manuscript.
Acknowledgements
The authors thank all of the AS patients and controls who gave generously
of their time to participate in this study. They would also like to thank Debra
McNamara for coordinating the collection of phenotype data and blood
samples from AS patients; Vicky Phillips, Jeremy Rossak, and Marilyn
Merriman for recruitment of controls and extraction of DNA; and Janine
Francis, Heather Fagg, and Judith McPhail for assistance with recruitment
and data collection. Thanks also to Dr Philip Robinson for his observations
on HLA-B27 prevalence data.
Financial support for this study was provided by a programme grant from
the Health Research Council of New Zealand (grant number 11/1075).
Author details
1Department of Surgical Sciences, Dunedin School of Medicine, University of
Otago, PO Box 913, Dunedin 9054, New Zealand. 2Department of
Biochemistry, University of Otago, PO Box 56, Dunedin 9056, New Zealand.
3Department of Medicine, University of Otago, PO Box 7343, Wellington
6242, New Zealand. 4Wellington Regional Rheumatology Unit, Hutt Hospital,
Private Bag 31907, Lower Hutt 5040, New Zealand. 5Department of
Rheumatology Waikato Hospital, Private Bag 3200, Hamilton 3240, New
Zealand. 6Department of Rheumatology and Immunology Christchurch
Hospital, PO Box 4710, Christchurch 8140, New Zealand. 7Department of
Medicine, Christchurch School of Medicine, PO Box 4345, Christchurch 8140,
New Zealand. 8Department of Rheumatology Timaru Hospital, Private Bag
911, Timaru, Dunedin, New Zealand. 9Department of Rheumatology,
Dunedin Hospital, Private Bag 1921, Dunedin 9054, New Zealand.
10Department of Medicine, Dunedin School of Medicine, PO Box 56,
Dunedin 9054, New Zealand.Received: 17 February 2013 Accepted: 27 September 2013
Published: 22 October 2013References
1. Thomas GP, Brown MA: Genetics and genomics of ankylosing spondylitis.
Immunol Rev 2010, 233:162–180.
2. Brown MA, Kennedy LG, MacGregor AJ, Darke C, Duncan E, Shatford JL,
Taylor A, Calin A, Wordsworth P: Susceptibility to ankylosing spondylitis in
twins: the role of genes, HLA, and the environment. Arthritis Rheum 1997,
40:1823–1828.
3. Gonzalez-Roces S, Alvarez MV, Gonzalez S, Dieye A, Makni H, Woodfield DG,
Housan L, Konenkov V, Abbadi MC, Grunnet N, Coto E, Lopez-Larrea C:
HLA-B27 polymorphism and worldwide susceptibility to ankylosing
spondylitis. Tissue Antigens 1997, 49:116–123.
4. Khan MA: HLA-B27 and its subtypes in world populations. Curr Opin
Rheumatol 1995, 7:263–269.
5. Mathieu A, Cauli A, Fiorillo MT, Sorrentino R: HLA-B27 and ankylosing
spondylitis geographic distribution as the result of a genetic selection
induced by malaria endemic? A review supporting the hypothesis.
Autoimmun Rev 2008, 7:398–403.
6. Brown MA, Pile KD, Kennedy LG, Calin A, Darke C, Bell J, Wordsworth BP,
Cornelis F: HLA class I associations of ankylosing spondylitis in the white
population in the United Kingdom. Ann Rheum Dis 1996, 55:268–270.
7. Niederer R, Danesh-Meyer H: Uveitis screening: HLAB27 antigen and
ankylosing spondylitis in a New Zealand population. N Z Med J 2006,
119:U1886.
8. Stewart AG: HLA-B27 polymorphism associated with disease in a
New Zealand population. NZ J Med Lab Science 2010, 64:78–84.
9. Reveille JD, Hirsch R, Dillon CF, Carroll MD, Weisman MH: The prevalence of
HLA-B27 in the US: data from the US National Health and Nutrition
Examination Survey, 2009. Arthritis Rheum 2012, 64:1407–1411.
10. van der Linden S, Valkenburg HA, Cats A: Evaluation of diagnostic criteria
for ankylosing spondylitis. A proposal for modification of the New York
criteria. Arthritis Rheum 1984, 27:361–368.
11. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A: A new
approach to defining disease status in ankylosing spondylitis: the Bath
Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994,
21:2286–2291.
12. Jones SD, Calin A, Steiner A: An update on the Bath Ankylosing
Spondylitis Disease Activity and Functional Indices (BASDAI, BASFI):
excellent Cronbach’s alpha scores. J Rheumatol 1996, 23:407.
13. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A:
Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS
Metrology Index. J Rheumatol 1994, 21:1694–1698.
14. Hollis-Moffatt JE, Xu X, Dalbeth N, Merriman ME, Topless R, Waddell C,
Gow PJ, Harrison AA, Highton J, Jones PB, Stamp LK, Merriman TR:
Role of the urate transporter SLC2A9 gene in susceptibility to gout in
New Zealand Maori, Pacific Island, and Caucasian case–control sample
sets. Arthritis Rheum 2009, 60:3485–3492.
15. Jones GT, Thompson AR, van Bockxmeer FM, Hafez H, Cooper JA,
Golledge J, Humphries SE, Norman PE, van Rij AM: Angiotensin II type 1
receptor 1166C polymorphism is associated with abdominal aortic
aneurysm in three independent cohorts. Arterioscler Thromb Vasc Biol
2008, 28:764–770.
16. Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, Oppermann U,
Dilthey A, Pirinen M, Stone MA, Appleton L, Moutsianas L, Leslie S,
Wordsworth T, Kenna TJ, Karaderi T, Thomas GP, Ward MM, Weisman MH,
Farrar C, Bradbury LA, Danoy P, Inman RD, Maksymowych W, Gladman D,
Rahman P, Spondyloarthritis Research Consortium of Canada, Morgan A,
Marzo-Ortega H, Bowness P, et al: Interaction between ERAP1 and HLA-B27
in ankylosing spondylitis implicates peptide handling in the mechanism for
HLA-B27 in disease susceptibility. Nat Genet 2011, 43:761–767.
17. International Genetics of Ankylosing Spondylitis Consortium, Cortes A,
Hadler J, Pointon JP, Robinson PC, Karaderi T, Leo P, Cremin K, Pryce K,
Harris J, Lee S, Joo KB, Shim SC, Weisman M, Ward M, Zhou X, Garchon HJ,
Chiocchia G, Nossent J, Lie BA, Forre O, Tuomilehto J, Laiho K, Jiang L,
Liu Y, Wu X, Bradbury LA, Elewaut D, Burgos-Vargas R, Stebbings S, et al:
Identification of multiple risk variants for ankylosing spondylitis through
high-density genotyping of immune-related loci. Nat Genet 2013,
45:730–738.
Roberts et al. Arthritis Research & Therapy 2013, 15:R158 Page 7 of 7
http://arthritis-research.com/content/15/5/R15818. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J,
Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: a tool set for whole-genome
association and population-based linkage analyses. Am J Hum Genet 2007,
81:559–575.
19. Friedlaender JS, Friedlaender FR, Reed FA, Kidd KK, Kidd JR, Chambers GK,
Lea RA, Loo JH, Koki G, Hodgson JA, Merriwether DA, Weber JL:
The genetic structure of Pacific Islanders. PLoS Genet 2008, 4:e19.
20. Chou CT, Chen JM, Hsu CM, Chen SJ: HLA-B27 and its subtypes in 4
Taiwanese Aborigine tribes: a comparison to Han Chinese patients with
ankylosing spondylitis. J Rheumatol 2003, 30:321–325.
21. Bakland G, Nossent HC, Gran JT: Incidence and prevalence of ankylosing
spondylitis in Northern Norway. Arthritis Rheum 2005, 53:850–855.
doi:10.1186/ar4341
Cite this article as: Roberts et al.: Prevalence of HLA-B27 in the New
Zealand population: effect of age and ethnicity. Arthritis Research &
Therapy 2013 15:R158.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
